Lunsumio (mosunetuzumab-axgb) / Roche, Biogen - LARVOL DELTA

GOLD: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Danielle Wallace | Initiation date: Apr 2025 ➔ Sep 2025

Circulating tumor DNA • Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Recent Development in Bispecific Antibody Immunotherapy for Hematological Malignancies. (PubMed, Crit Rev Oncol Hematol) - "Leading BsAbs, including mosunetuzumab, glofitamab, and blinatumomab, have demonstrated promising efficacy in clinical trials for leukemia and lymphoma subtypes. Despite remaining challenges, particularly in acute myeloid leukemia (AML), ongoing research into new targets and combination therapies is expected to enhance the efficacy of BsAbs in relapsed or refractory (R/R) disease. This review explores the structural and functional innovations of BsAbs, the challenges in current therapies, and their transformative potential in hematological malignancy immunotherapy."

Journal • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology

Fixed–duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a Phase II study of relapsed/refractory post–BTKi mantle cell lymphoma (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Mosunetuzumab (mosun) Produces Durable Benefit in Patients (pts) with Newly Diagnosed Follicular Lymphoma (FL): Extended Follow up of the MITHIC–FL1 Trial (ICML 2025) - No abstract available

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Mosunetuzumab (Mosun) demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL) (ICML 2025) - No abstract available

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

CTEP Trial 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant B-Cell Lymphoma • Oncology

MARSUN, a Phase III, Multicenter, Open Label, Randomized Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in R/R marginal zone lymphomas. (ICML 2025) - No abstract available

Clinical • P3 data • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic countries (MERLIN) (ICML 2025) - No abstract available

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Machine Learning Based Unsupervised Multimodal Analysis Identifies Patient Subsets Associated with Response to Mosunetuzumab in Relapsed/Refractory NHL (ICML 2025) - No abstract available

Clinical • Machine learning • Lymphoma • Non-Hodgkin’s Lymphoma

An ongoing Phase Ib trial assessing mosunetuzumab monotherapy and combined mosunetuzumab and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia (ICML 2025) - No abstract available

Clinical • Monotherapy • P1 data • Hematological Malignancies • Lymphoma • Oncology

Fixed duration subcutaneous mosunetuzumab in patients with previously untreated high–tumor burden follicular lymphoma: interim results from the Phase II MorningSun study (ICML 2025) - No abstract available

Clinical • P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Tisagenlecleucel Versus Mosunetuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): A Matching-Adjusted Indirect Comparison (MAIC) Using 3-Year Follow-up Data (ICML 2025) - No abstract available

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

High Complete Response Rates and Differential Toxicity of Mosunetuzumab and Lenalidomide in Previously Untreated Follicular (FL) and Marginal Zone Lymphoma (MZL) (ICML 2025) - No abstract available

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology

Fixed-duration subcutaneous mosunetuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with high-risk features: pivotal Phase II study update (ICML 2025) - No abstract available

Clinical • P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Safety and efficacy of mosunetuzumab subcutaneous maintenance following mosunetuzumab plus lenalidomide induction therapy in previously untreated follicular lymphoma (ICML 2025) - No abstract available

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Real-world outcomes of mosunetuzumab use from the CUBIC consortium (ICML 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Lymphoma

Efficacy and Safety of Subcutaneous Mosunetuzumab Monotherapy and in Combination with Lenalidomide in Japanese Patients with Relapsed or Refractory Follicular Lymphoma (ICML 2025) - No abstract available

Clinical • Combination therapy • Monotherapy • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Fixed duration subcutaneous (SC) mosunetuzumab had better practice efficiency vs treat to progression epcoritamab SC in 3L+ follicular lymphoma (FL): an economic analysis (ICML 2025) - No abstract available

HEOR • Omic analysis • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Impact of tumor burden and prior venetoclax treatment on mosunetuzumab-mediated tumor control in relapsed/refractory CLL (ICML 2025) - No abstract available

Lymphoma • Oncology

Fixed-duration subcutaneous mosunetuzumab had similar efficacy but lower cytokine release syndrome risk vs epcoritamab in 3L+ follicular lymphoma: an indirect comparison (ICML 2025) - No abstract available

Clinical • Cytokine release syndrome • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05207670 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Biomarker • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial (clinicaltrials.gov) - P2 | N=22 | Not yet recruiting | Sponsor: University of Washington

New P2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Time Toxicity of Bispecific Antibody (BsAb) Options in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Fixed-Duration Mosunetuzumab Versus Treat to Progression Epcoritamab (ISPOR 2025) - "Overall, fixed-duration mosunetuzumab had fewer HC days and more home days than treat to progression epcoritamab. These data provide important considerations to ensure more patient-centered treatment choices can be made."

Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Novel Coronavirus Disease • Oncology

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma. (PubMed, Clin Transl Sci) - P1/2 | "Therefore, dose adjustment of the globally approved mosunetuzumab regimen is not warranted for Chinese patients with R/R FL. Trial Registration: ClinicalTrials.gov identifier: NCT02500407."

Journal • PK/PD data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20 • IL6 • TNFA